Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Operating Leases (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Operating Leases for 3 consecutive years, with $7.9 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 25.42% to $7.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.9 million through Dec 2025, down 25.42% year-over-year, with the annual reading at $7.9 million for FY2025, 25.42% down from the prior year.
  • Operating Leases for Q4 2025 was $7.9 million at Artiva Biotherapeutics, down from $8.5 million in the prior quarter.
  • The five-year high for Operating Leases was $13.3 million in Q4 2023, with the low at $7.9 million in Q4 2025.
  • Average Operating Leases over 3 years is $10.4 million, with a median of $10.4 million recorded in 2024.
  • Peak annual rise in Operating Leases hit 19.27% in 2025, while the deepest fall reached 25.42% in 2025.
  • Over 3 years, Operating Leases stood at $13.3 million in 2023, then decreased by 20.62% to $10.6 million in 2024, then dropped by 25.42% to $7.9 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $7.9 million, $8.5 million, and $9.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.